Wednesday, July 8, 2026

pharma · COVID-19 · Poliomyelitis

Sinovac Research and

Sinovac Research and clinical programs — 115 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Dhaka, CN
Founded
2022
Employees
9
Programs
115
Drugs
54
Patents
0
Intelligence · Clinical Programs

Sinovac Research and projects

115 ClinicalTrials.gov programs sponsored by Sinovac Research and.

Sinovac Research and has 115 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 3
  1. PRO-nCOV-2009

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial
  2. SA55 Injection

    Sinovac Research and Development Co.,

    Infection of Upper Respiratory Tract Caused by 2019-nCoV

    phase 2 small molecule active

    1 trial
  3. SNA02-48

    Sinovac Research and Development Co.,

    Tetanus

    phase 2 mab active

    1 trial
  4. Single-dose regimen of high dosage investigational sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 2 mab completed

    1 trial
  5. Sinovac Low-dosage PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab completed

    1 trial
  6. Sinovac PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab active

    2 trials
  7. pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Sinovac Research and Development Co.,

    Pandemic Influenza

    phase 2 mab completed

    1 trial
  8. 100U inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Hand-foot-mouth Disease

    phase 1 mab completed

    1 trial
  9. Inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Infection; Viral, Enterovirus

    phase 1 mab completed

    1 trial
  10. Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    phase 1 mab completed

    1 trial
  11. Low-dose RSV mRNA vaccine

    Sinovac Research and Development Co.,

    RSV

    phase 1 mab active

    1 trial
  12. One dose of investigational vaccine

    Sinovac Research and Development Co.,

    Hepatitis B

    phase 1 mab completed

    1 trial
  13. PRO-PanFlu-1001

    Sinovac Research and Development Co.,

    Influenza

    phase 1 mab completed

    1 trial
  14. SA55 Injection

    Sinovac Research and Development Co.,

    COVID-19

    phase 1 small molecule active

    1 trial
  15. SA55 nasal spray

    Sinovac Research and Development Co.,

    COVID-19

    phase 1 small molecule active

    1 trial
  16. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials
  17. high-dose Group ACYW135X Meningococcal Conjugate Vaccine

    Sinovac Research and Development Co.,

    Meningococcal Meningitis

    phase 1 mab active

    1 trial
  18. pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Sinovac Research and Development Co.,

    Pandemic Influenza Vaccine

    phase 1 mab completed

    1 trial
  19. 2 doses of HAV

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial
  20. 2012-2013 trivalent seasonal influenza vaccine

    Sinovac Research and Development Co.,

    Influenza

    approved mab completed

    1 trial
  21. 2wIPV+1sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    approved mab active

    1 trial
  22. 5000 volunteers (6-35 months)-EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial
  23. Adult group in immunogenicity and safety study of combined immunization

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial
  24. COVID-19 Vaccine (Vero cell), Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial
  25. Concomitant administration of EV71 vaccine with EPI vaccines

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial
  26. Concomitant administration of EV71vaccine with EPI vaccines

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial
  27. EV71 Vaccine

    Sinovac Research and Development Co.,

    EV71 Vaccine

    approved mab completed

    1 trial
  28. EV71 inactived vaccine(Vero cells)

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial
  29. EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial
  30. Experimental 23-valent PPV

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial
  31. Experimental 23-valent Pneumococcal

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial
  32. Experimental Group

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    4 trials
  33. Experimental Vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab active

    1 trial
  34. Experimental vaccine 1

    Sinovac Research and Development Co.,

    COVID-19

    approved mab on hold

    1 trial
  35. H1N1 influenza A Vaccine (PANFLU.1)

    Sinovac Research and Development Co.,

    Influenza

    approved mab completed

    1 trial
  36. Healive+Healive

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial
  37. Healive® Lot 1

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial
  38. High-dosage SARS-CoV-2 vaccine

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial
  39. Inactivated HAV vaccine

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial
  40. Inactivated Hepatitis A vaccine (HAV)

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial
  41. Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial
  42. Inactivated SARS-CoV-2 Vaccine (Vero cell)

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial
  43. Investigational 23-valent PPV

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    2 trials
  44. Investigational live attenuated varicella vaccine

    Sinovac Research and Development Co.,

    Varicella

    approved mab active

    4 trials
  45. Live attenuated varicella vaccine

    Sinovac Research and Development Co.,

    Varicella

    approved mab active

    3 trials
  46. Mumps vaccine

    Sinovac Research and Development Co.,

    Mumps

    approved mab completed

    1 trial
  47. Mumps vaccine, Live (MV)

    Sinovac Research and Development Co.,

    Mumps

    approved mab active

    1 trial
  48. PRO-HAV-MA4001-LN

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab active

    1 trial

Frequently asked questions

How many clinical projects does Sinovac Research and have?

115 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.